Search Results

The product title you are looking for is no longer available. Other similar products that may interest you are listed below:

Refine your Search

Results for 'Bolder BioTechnology Inc -Company Report'
Title Publication Date Price Relevance
Bolder BioTechnology, Inc.-Therapeutic Competitors Report Mar 2011 £220 100%
Bolder BioTechnology, Inc.-Deals & Alliances Report Mar 2011 £380 99%
Neutropenia - Pipeline Review
H2 2011
 Oct 2011 £315 79%
Lipodystrophy - Pipeline Review
H2 2011
 Oct 2011 £315 77%
Growth Hormone Deficiency - Pipeline Review
H2 2011
 Oct 2011 £315 71%
Multiple Sclerosis - Pipeline Review
H2 2011
 Sep 2011 £315 69%
Anemia - Pipeline Review
H2 2011
 Sep 2011 £315 68%
Interferon
Competitor Analysis
 Feb 2011 £375 68%
Growth Factors ( Blood And Tissue ) Jan 2011 £2,845 66%
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review
H1 2012
 Jan 2012 £325 66%
Chemotherapy Effects - Pipeline Review
H1 2012
 Jan 2012 £325 65%
Erythropoietin (EPO)
Competitor Analysis
 Jan 2011 £415 63%
Ovarian Cancer - Pipeline Review
H1 2012
 Jan 2012 £325 62%
Growth Factors (Blood and Tissue)
A World Report
 Nov 2009 £1,895 62%
Global Protein Therapeutics Market, The
Market Dynamics and Pipeline Analysis
 Dec 2006 £1,895 43%